Navigation Links
Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
Date:8/11/2008

LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire-FirstCall/ --

- Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin Testing in U.S. Animal Models

An internationally renowned avian influenza expert today hailed "encouraging and exciting" results from experiments conducted by his research team. This study demonstrated impressive efficacy of a novel statin/caffeine combination, StatC(TM) in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse model.

To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/canopusbiopharma/34441/

Dr. Jiahai Lu, from the School of Public Health, Sun Yat-sen University in Guangzhou, China, has published extensively in the field of avian influenza, and has been researching the breakthrough compound StatC(TM) for the past two years on behalf of Canopus Biopharma (OTCPK:CBIA), a US corporation who discovered and patented the potential of this antiviral candidate.

"The global distribution of the highly pathogenic H5N1 avian influenza has caused the World Health Organization to show its profound concern regarding the possibility of the virus spreading from human to human in the future," stated Dr. Lu. "Furthermore, the development of resistance to two approved anti-influenza drugs, oseltamivir (Tamiflu(R)) and zanamivir (Relenza(R)), as well as the lack of adequate vaccines has increased the need of developing new antiviral drugs."

"Consequently, I am delighted to be involved in the preclinical research stage of this innovative antiviral candidate, and look forward to continuing our successful collaboration with Canopus Biopharma in this area."

Dr. Lu and his colleagues have conducted extensive animal studies with StatC(TM) against three influenza strains, H5N1 (avian influenza, bird flu), H1N1 (Spanish influenza) and H3N2 (Hong Kong influe
'/>"/>

SOURCE Canopus Biopharma INC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
4. ARCA biopharma Appoints James Carr as Vice President of Marketing
5. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
6. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
7. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
8. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
9. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
10. Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... July 31 InNexus,Biotechnology Inc., (TSX VENTURE: ... a drug development company commercializing the,next generation ... Cross Linking,(DXL(TM)) technology, will present at IBC,s ... of Innovative Therapeutics (DDT) Conference being,held in ...
... BERKELEY HEIGHTS, N.J., July 31 Genta,Incorporated (OTC ... release its second quarter 2008 financial results on ... conference call and live audio,webcast to discuss these ... Participants can access the live call by ...
... Amicus Therapeutics,(Nasdaq: FOLD ), a biopharmaceutical company ... of human,genetic diseases, will announce second quarter 2008 ... Thursday, August 7, 2008. The results,announcement will be ... that,afternoon at 5 p.m. EDT., Interested participants ...
Cached Biology Technology:InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 3Amicus Therapeutics Announces Second Quarter 2008 Results Release Date 2
(Date:7/11/2014)... American Society for Bone and Mineral Research awarded Michael ... Medicine (BUSM), with the 2014 Louis V. Avioli Award. ... BUSM, is internationally known for revolutionizing the understanding of ... , The award honors a member of the American ... contributions to bone and mineral basic research. It is ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... that remains unusually stable in the body, researchers at ... to the development of therapeutic RNA nanotechnology. Peixuan ... and professor of biomedical engineering, and his colleagues in ... construction of a thermodynamically stable RNA nanoparticle online in ...
... it turns out, suppresses melatonin 5 times more than exposure ... off an orange-yellow light. "Just as there are regulations and ... rules for the pollution stemming from artificial light at night," ... "White" light bulbs that emit light at shorter wavelengths ...
... Findings, published today in Nature and ... Pressure Genome-Wide Association Studies represent a major advance in our ... new potential therapeutic targets for prevention of heart disease and ... Research published in Nature and co-led by scientists ...
Cached Biology News:Team finds stable RNA nano-scaffold within virus core 2Dangers of exposure to 'white' light 2Dangers of exposure to 'white' light 3Discovery of blood pressure genes could help prevent cardiovascular disease 2Discovery of blood pressure genes could help prevent cardiovascular disease 3
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
NORMAL DONOR DONKEY SERUM...
... Molecular Probes Fc OxyBURST Green reagent (F-2902) ... of Boston University to permit measurement of ... and the subsequent oxidative burst directly in ... reagent consists of bovine serum albumin (BSA) ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: